Introduction {#s1}
============

Atopic dermatitis (AD) is a common inflammatory skin disease, characterized by epidermal dysfunction and T-helper 2 (Th2)/Th22-predominant inflammation, with variable increases in Th1 and Th17 ([@B1]--[@B11]). Dupilumab, a monoclonal antibody that targets IL-4Rα, inhibiting IL-4/IL-13 signaling, has demonstrated both clinical efficacy and modulation of Th2 cytokines (e.g., IL-13, CCL17, CCL18, CCL26) and other inflammatory mediators in skin from AD patients ([@B1], [@B12]--[@B14]). However, these molecular studies used biopsies, which are associated with pain, scarring, and increased risk of infection. Hence, there is a need for less invasive skin sampling techniques for monitoring therapeutic response in real-life, clinical trials, and longitudinal studies.

Tape-stripping, a minimally invasive approach that samples the stratum corneum and upper stratum granulosum ([@B15], [@B16]), has been used to evaluate AD skin biomarkers, almost exclusively in untreated patients ([@B16]--[@B26]). Koppes et al. reported decreases in Th2 markers (e.g., IL-4, IL-13, CCL22) after local application of emollient to the skin ([@B27]). However, to our knowledge, tape-strips have not yet been utilized to assess changes in the AD cutaneous profile in response to systemic targeted therapeutics like dupilumab.

Recently, we used the Olink multiplex assay to characterize the cutaneous proteomic profile of a large panel of \~350 inflammatory proteins in skin biopsies from untreated moderate-to-severe AD patients, requiring only 10 ng of tissue ([@B28]). Thus, far, this platform has not been used to analyze tape-strips, or to measure therapeutic response in inflammatory skin conditions.

In this real-life study, we used Olink to define the proteomic signature of 26 moderate-to-severe AD patients in tape-strips collected from lesional/non-lesional skin, before and after 16 weeks of dupilumab treatment. Dupilumab therapy resulted in significant reductions in products of pathogenic immune axes (e.g., Th2, Th17) and in markers that have been implicated as prognostic or therapeutic targets of atherosclerosis and cardiovascular disease (CVD).

Methods {#s2}
=======

Study Population
----------------

Twenty-six Caucasian patients with atopic dermatitis (AD) \[four female/22 male; age range, 18--65 years \[mean, 41.2 years\]; mean EASI 19.2\] initiating treatment with dupilumab at the Department of Dermatology, Bispebjerg Hospital, Denmark, between March 2018 and June 2019 were enrolled under institutional review board-approved protocols ([Table 1](#T1){ref-type="table"}). The patients were treated with subcutaneous injections of 300 mg dupilumab every 2 weeks for 16 weeks, after a loading dose of 600 mg (label use). To be considered for dupilumab treatment, patients had to meet the following criteria: AD according to the UK-criteria, age ≥ 18 years, and history of failed treatment with two or more traditional systemic immunosuppressive therapies. Of note, all enrolled patients reported no history of other known inflammatory skin (e.g., psoriasis), autoimmune (e.g., rheumatoid arthritis), or systemic disease (e.g., cardiovascular disease, coronary, or carotid artherosclerosis). The use of topical anti-inflammatory treatments and emollients was prohibited seven days and 24 h prior to each evaluation, respectively. Twenty-three patients had not received treatment with phototherapy or systemic immunosuppressive drugs 4 weeks prior to dupilumab treatment, while two patients had been treated with prednisolone and one with methotrexate within 4 weeks of the first visit.

###### 

Demographic Table.

  **Characteristic**   **Atopic dermatitis: Baseline (*n = 26*)**   **Atopic dermatitis: Post-treatment**   **P-value**
  -------------------- -------------------------------------------- --------------------------------------- -------------
  Age, mean ±SD        41.2 ± 11.0                                  --                                      
  Gender                                                                                                    
  Female               4                                            --                                      
  Male                 22                                                                                   
  EASI, mean ±SD       19.2 ± 8.3                                   5.3 ± 5.5                               4.12E-09

*EASI, Eczema Area and Severity Index; SD, Standard deviation*.

Tape-Strip Collection and Protein Extraction
--------------------------------------------

Patients were evaluated before and 16 weeks after initiating treatment with dupilumab. At each visit, thirty consecutive tape-strips (D-Squame 3.8 cm^2^, CuDerm) were collected from representative lesions and non-lesional skin on the upper or lower extremities, and were serially labeled. Each tape was pressed against skin for 10 s with a standardized pressure (225 gr/cm^2^), before being stripped from the skin. Tapes number 3 and 18 were pooled together and used for subsequent protein extraction. For each sample, tapes 3 and 18 were cut into quarters and placed in 8 tubes. 300 μL of Ripa buffer were added to the first quarter, followed by 15 min sonification in iced water (0--4°C) in an ultrasonic bath. The extract was then transferred to the next quarter followed by 15 min sonification. This was repeated a total of eight times for each sample.

Olink Proteomic Analysis
------------------------

For each sample, 10 ng of protein was lysed in 90 μL of protein extract, and was analyzed using the high-throughput proteomic OLINK Proseek® multiplex assay (a proximity extension assay using oligonucleotide-labeled antibody probe pairs) ([@B29]). Pre-selected Inflammation and Cardiovascular disease (CVDII/III) panels were assessed, as previously described, comprising a total of 353 proteins ([@B28], [@B30]).

Statistical Analysis
--------------------

A power calculation from a published Olink study that evaluated patients with AD ([@B28]) showed that a sample size of 25 subjects would allow us to detect differences in lesional compared to non-lesional skin in Th2 (CCL13, CCL17), Th1 (CXCL9, CXCL10), and atherosclerosis/cardiovascular risk markers (SELE/E-selectin, SELP/P-selectin, RETN/resistin) with more than 90% power (at significance level 0.05). Statistical analyses were performed using R software ([www.R-project.org](http://www.R-project.org)) and packages available through Bioconductor ([www.bioconductor.org](http://www.bioconductor.org)). Fold-changes were estimated, and hypothesis testing was conducted using contrasts under the general framework for linear models in the *limma* package. *P*-values were adjusted for multiple hypotheses using the Benjamini-Hochberg procedure, controlling for false discovery rate (FDR). Proteins with fold-change \>1.5 and FDR \< 0.05 were considered differentially expressed. Unsupervised hierarchical clustering of mean expression profiles was performed with Euclidean distance and a McQuitty agglomeration scheme, and represented by a heatmap and accompanying dendrogram. Previously published protein sets of Th1, Th2, Th17, and atherosclerosis/cardiovascular risk proteins were quantified by gene-set variation analysis (*gsva* package), and expressed as z-scores ([@B1], [@B28]). Spearman correlations were used to assess correlations between percent improvement of clinical severity scores and percent change in protein expression levels.

Results {#s3}
=======

Overall Clinical Improvement and Proteomic Changes in AD Patients After Dupilumab Therapy
-----------------------------------------------------------------------------------------

Twenty-six adults with moderate-to-severe AD were included in this study (mean age 41.2 years, four female/22 male, mean EASI: 19.2) ([Table 1](#T1){ref-type="table"}). Overall, AD patients experienced significant clinical improvement, with mean percentage reduction in EASI score of 72.4% (*P* \< 0.001) after 16 weeks of dupilumab therapy, consistent with previously reported efficacy of dupilumab in AD ([Table 1](#T1){ref-type="table"}) ([@B1]).

Tape-stripped lesional and non-lesional skin samples were analyzed with the Olink proteomic assay before and after treatment, measuring 353 inflammatory proteins. Using criteria of fold-change \> 1.5 and FDR \< 0.05, we identified 184 up-regulated proteins in lesional vs. non-lesional AD at baseline, of which 136 proteins significantly decreased after dupilumab therapy in lesional and/or non-lesional skin ([Table S1](#SM1){ref-type="supplementary-material"}). Dupilumab therapy induced an overall mean improvement of 66.2% in lesional vs. non-lesional proteome.

Dupilumab Suppressed Activation of Th2 and Th17/Th22, but Not Th1 Immune Pathways
---------------------------------------------------------------------------------

Proteins that showed the greatest differential expression at baseline or with treatment, and are known to be part of immune or atherosclerosis/cardiovascular signaling pathways ([@B1], [@B28], [@B31]), are depicted in an unsupervised hierarchical clustering heatmap ([Figure 1](#F1){ref-type="fig"}). Several cellular markers of immune cell infiltration were elevated in lesional vs. non-lesional skin at baseline, and significantly decreased in lesional skin after dupilumab. These included markers of macrophages (CSF1, CD163), DCs (CLEC10A, CD40, TNF), and T-cells (CD4, CD5, GZMA) ([Figure 1](#F1){ref-type="fig"}, [Table S1](#SM1){ref-type="supplementary-material"}).

![Heatmap of immune and atherosclerosis/cardiovascular proteins. Heatmap of immune and atherosclerosis and cardiovascular signaling proteins that are differentially expressed in tape-stripped skin of atopic dermatitis patients before and after dupilumab therapy, using the criteria of fold-change \>1.5 and false discovery rate \<0.05. Proteins are ordered by unsupervised hierarchical clustering, as represented by dendrogram on the left. The table on the right shows fold-changes in lesional vs. non-lesional tape-strips at baseline (LS vs. NL), and post- vs. pre-treatment with dupilumab (Post-Rx vs. Pre-Rx) for both non-lesional and lesional skin. LS, Lesional; NL, Non-lesional; Rx, Treatment.\*\*\*FDR \< 0.001, \*\*FDR \< 0.01, \*FDR \< 0.05, +FDR \< 0.1.](fimmu-11-01768-g0001){#F1}

Immune proteins related to general inflammation (MMP12), T-cell activation/migration (IL-2RA, CCL19, TNFRSF9, EZR), Th2 (CCL13, CCL17, CCL23, IL-1RL1/ST2/IL-33R), Th17/Th22 (IL-12B, IL-17RA, CXCL1, KYNU, S100A12), and innate immunity (IL-6, IL-8, IL-17C, IL-6R) similarly displayed significant increases at baseline and significant reductions in lesions after dupilumab treatment ([Figure 1](#F1){ref-type="fig"}, [Table S1](#SM1){ref-type="supplementary-material"}). CCL2 and CCL3, which signal via both Th1 and Th2 pathways, were up-regulated at baseline and significantly suppressed after dupilumab in tape-stripped lesions, while the Th1 chemokines CXCL9 and CXCL10 were initially up-regulated in lesional vs. non-lesional tape-stripped skin at baseline, but did not change significantly with treatment.

Few immune markers demonstrated significant reductions with dupilumab therapy in tape-strips collected from non-lesional skin. These included the DC marker CD40, and Th2 chemokine CCL17, with a trend toward significance (FDR \< 0.1) for macrophage/DC markers (CD163, CLEC10A), Th2 chemokine CCL13, and Th1/Th2 chemokine CCL3 ([Figure 1](#F1){ref-type="fig"}, [Table S1](#SM1){ref-type="supplementary-material"}).

Dupilumab Decreased Inflammatory Proteins Related to Atherosclerosis Signaling and Cardiovascular Risk
------------------------------------------------------------------------------------------------------

Numerous proteins that have been linked to atherosclerosis and CVD showed up-regulation in baseline tape-stripped lesional skin, with significant suppression after dupilumab treatment ([Figure 1](#F1){ref-type="fig"}, [Table S1](#SM1){ref-type="supplementary-material"}). These included pro-atherogenic cytokines (IL-16, CCL2, CCL8), mediators of vascular adhesion and/or angiogenesis (SELE/E-selectin, SELP/P-selectin, VEGFA, HSPG2/perlecan, HGF/hepatocyte growth factor, PECAM1/platelet endothelial cell adhesion molecule-1, VWF/von Willebrand factor), and matrix metalloproteinases (MMPs) involved in atherosclerotic tissue remodeling (MMP1, MMP3, MMP9, MMP10). PECAM1 and MMP3 also demonstrated significant reductions with therapy in non-lesional skin, with a trend toward significance (FDR \< 0.1) for SELE/E-selectin.

Dupilumab significantly decreased levels of proteins previously described as prognostic markers or therapeutic targets of cardiovascular morbidity/mortality and cardiac injury in lesional skin, including TNFSF14/LIGHT, ALCAM/activated leukocyte cell adhesion molecule, IGFBP1/insulin-like growth factor binding protein-1, IGFBP2, IGFBP7, SORT1/sortilin, SERPINE1/plasminogen-activator inhibitor type-1 (PAI-1), CHIT1/chitotriosidase-1, PLAUR/uPAR, AXL/tyrosine-protein kinase receptor UFO, and RETN/resistin ([Figure 1](#F1){ref-type="fig"}, [Table S1](#SM1){ref-type="supplementary-material"}). Dupilumab also suppressed markers of cell-cell adhesion (CDH3/cadherin-3), apoptosis (CASP3/caspase-3, CASP8/caspase-8), and negative immune regulation (CD274/PD-L1).

Pathway Analysis Supports Protein Differential Expression by Olink
------------------------------------------------------------------

Gene-set variation analyses were performed using immune and atherosclerosis/cardiovascular-related pathways that were previously published ([Figure 2](#F2){ref-type="fig"}) ([@B1], [@B28], [@B31]). The Th2, Th17, and Th1 pathways were all highly enriched at baseline in lesional vs. non-lesional skin (FDR \< 0.01) ([Figures 2A--C](#F2){ref-type="fig"}). However, only Th2 and Th17, but not Th1, showed significant reductions after dupilumab treatment (FDR \< 0.001). For Th1, the lack of significant difference between the non-lesional group and post-treatment lesional group is likely due to the inclusion of markers that are co-regulated by other immune axes (e.g., CCL2 and CCL3 are co-regulated by Th1 and Th2). Dupilumab also significantly inhibited the pathway of atherosclerosis/cardiovascular risk-related proteins (FDR \< 0.001) ([Figure 2D](#F2){ref-type="fig"}).

![Gene-set variation analysis. Mean z-scores of the Th2 **(A)**, Th17 **(B)**, Th1 **(C)**, and atherosclerosis/cardiovascular risk **(D)** pathways in atopic dermatitis lesional and non-lesional tape-strips before and after dupilumb therapy, expressed as a boxplot. Red dots indicate mean values. Asterisks indicate significance between respective groups. AD, Atopic dermatitis; GSVA, Gene-set variation analysis; Rx, Treatment. \*\*\*FDR \< 0.001, \*\*FDR \< 0.01.](fimmu-11-01768-g0002){#F2}

Correlation Analyses Showed Strong Associations Between Lesional Protein Expression Changes and Clinical Improvement
--------------------------------------------------------------------------------------------------------------------

Spearman correlation analyses were performed to assess the associations between differences in protein expression levels in lesional tape-stripped skin and clinical severity, as measured by EASI. The differentially expressed proteins with the strongest correlations between percent decrease in expression level and percent improvement in EASI are depicted in [Figure 3](#F3){ref-type="fig"}. The percent improvement in EASI strongly correlated with the percent decrease in markers of macrophages (CSF1), Th2 (CCL13, CCL23), Th17 (KYNU), and innate immunity (IL-6R) (*r* \> 0.35, *P* \< 0.1). Similar correlations were observed for factors implicated in cardiovascular mortality and morbidity (IGFBP7, HSPG2/perlecan, SORT1/sortilin, AXL), as well as mediators of angiogenesis (VEGFA), apoptosis (CASP3), and cell-cell adhesion (CDH3) (*r* \> 0.35, *P* \< 0.1).

![Correlation plots. Spearman correlation scatter plots \[linear regression \[blue line\] with its confidence interval \[gray area\]\] for percent improvement in EASI score before and after dupilumab vs. percent decrease in protein expression levels, as measured by Olink. Upper left corner with r, Spearman correlation coefficient and p, associated *P*-value. EASI, Eczema Area and Severity Index.](fimmu-11-01768-g0003){#F3}

Discussion {#s4}
==========

In this first tape-strip proteomic profiling study that evaluates changes with dupilumab therapy, we discovered that dupilumab therapy resulted in alterations in important immunologic and atherosclerosis/cardiovascular proteins, many of which were also found in skin biopsies to be elevated at baseline or modulated by dupilumab therapy ([@B1], [@B6], [@B12], [@B28], [@B32]). This current study provides several novel findings. First, while tape-strips have been used to map the lesional and non-lesional AD cutaneous profiles at baseline ([@B16], [@B17]), tape-strips have never been utilized to track molecular response to targeted treatment. Furthermore, the Olink proteomic assay, recently used to profile skin biopsies ([@B28]), has not yet been applied to analysis of tape-strips. Compared to mRNA profiling, Olink enables quantification of specific proteins related to CVD, and perhaps also allows for detection of greater, more significant differences between lesional and non-lesional AD in tape-strips ([@B17]). Finally, this is the first cutaneous study characterizing changes in the AD proteomic profile in response to treatment.

Decreases in markers of T-cells/T-cell activation (CD4, IL-2RA), macrophages (CSF1, CD163), and DCs (CLEC10A, CD40) were observed in AD lesions after dupilumab therapy. These effects were not limited to lesions, as dupilumab also down-regulated expression of CD163, CLEC10A, and CD40 in clinically unaffected skin. IL-4 and IL-13 are proposed to have a role in directing maturation/activation of macrophages and DCs, including atopic DCs ([@B33], [@B34]). Dupilumab likely inhibits these pathways, resulting in diminished infiltration by immune cells in lesional and non-lesional skin.

Predictably, dupilumab induced significant reductions in key Th2 markers, including CCL13, CCL17, and IL-1RL1/ST2/IL-33R, consistent with its mechanism of action in inhibiting the Th2 axis via IL-4/IL-13 signaling. IL-1RL1, in particular, is also a prognostic factor for heart failure (HF) and myocardial infarction (MI) ([@B35]), forming a bridge between Th2 activation/allergy sensitization and CVD. Several Th17 products (IL-12B, CXCL1, KYNU) also decreased after dupilumab therapy, supporting the role of IL-4 in regulating Th17, suggesting that downstream signaling pathways via IL-4/IL-13 also influence the Th17 axis, possibly related to its regulation of DC differentiation. In contrast, the Th1/IFNG-related chemokines CXCL9 and CXCL10 remained unchanged, suggesting that dupilumab has a minimal effect on the Th1 pathway. Observed decreases in the Th1 chemokines CCL2 and CCL3 are likely due to their co-regulation by Th2 ([@B36], [@B37]). The Th2 and Th1 axes are known to have reciprocal effects on each other ([@B38], [@B39]), so Th2 inhibition with dupilumab may paradoxically relieve suppression of Th1. Notably, our proteomic data in tape-strips are consistent with mRNA profiling in skin biopsies, where dupilumab also reduced cellular T-cell/DC infiltrates and Th2/Th17 products, without appreciable Th1 modulation ([@B1], [@B12]).

Previous Olink studies have highlighted increased levels of atherosclerosis and cardiovascular-risk proteins in AD compared to healthy individuals in both blood and skin ([@B28], [@B30], [@B31], [@B40]). From these studies, we postulated that these inflammatory proteins originate in the skin, but spill into the blood, where they induce pro-inflammatory effects systemically. However, it has yet to be determined whether these abnormalities are affected by dupilumab or any other treatment. Here, we present data indicating that many atherosclerosis and cardiovascular risk-related proteins that were found to be up-regulated in other Olink studies (e.g., SELE/E-selectin, TNFSF14/LIGHT, VEGFA, RETN/resistin, MMPs) are in fact suppressed by dupilumab in tape-stripped skin lesions ([@B28], [@B30], [@B31], [@B40]).

We further identified additional proteins that may be implicated in cardiovascular mortality or morbidity, but have not been linked to AD in the past. For example, IGFBP7 was recently found to be more elevated in patients with MI, and may be a good biomarker of coronary artery disease (CAD) occurrence ([@B41]). High serum levels of ALCAM were independently associated with an increased risk of cardiovascular death in acute coronary syndrome ([@B42]). CHIT1/chitotriosidase-1, secreted by activated macrophages, is expressed at higher levels in patients with atherosclerosis in a severity-dependent manner ([@B43]), and may be a predictor of endothelial dysfunction and insulin resistance in type 2 diabetes ([@B44]). PLAUR/uPAR, which is expressed by vascular endothelial cells and is involved in atherosclerotic plaque destabilization, outperformed CRP in predicting CVD ([@B45], [@B46]). High serum levels of PAI-1, encoded by SERPINE1, suppresses fibrinolysis and may thus increase the risk of CAD ([@B47]), and is also an independent risk factor for reinfarction in patients who survived an early MI ([@B48]). Finally, AXL, which may be a mediator of myocardial damage, had higher expression in patients with HF, and may be associated with worse HF prognosis ([@B49]). Taken together, dupilumab modified lesional skin expression of various prognostic markers and potential therapeutic targets of CVD, highlighting these as potential biomarkers of therapeutic response in AD, requiring further exploration in future studies. Furthermore, these decreases in skin may precede longer-term effects in AD patients, like decreased risk of future cardiac complications, also meriting further investigation with larger longitudinal studies. If these markers in skin indeed have prognostic value for systemic inflammation and CVD burden, the fact that they are quantifiable by minimally invasive tape-strips would have vast applications in diagnosis and clinical evaluation of not just AD, but other inflammatory skin and systemic diseases.

This study had a few limitations. Patients were only followed up at 16 weeks, while longer-term follow-up would be beneficial to assess the persistence of proteomic changes induced by dupilumab. Additionally, protein quantification in this study was limited to 353 proteins. The investigated panels did not include important Th22 markers like IL-22, therefore precluding careful examination of the Th22 axis. We also did not assess a placebo group, since our study simulated a real-life experience. Finally, our sample size, while relatively small, is powered to detect significant differences in important disease-related markers. Validation of these findings with a larger cohort in the future would be beneficial.

In summary, we present the first study investigating changes in the proteomic signature of tape-strips collected from lesional/non-lesional AD skin before and after dupilumab therapy. Our data showed treatment-related suppression of key immune and atherosclerosis/cardiovascular risk proteins, further correlating with clinical improvement. These data emphasize the potential utility of tape-strip proteomic profiling for tracking biomarkers of therapeutic response in real-life settings as well as clinical trials and longitudinal studies of AD and beyond.
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